Cannabis compounds may limit stroke damage

Posted on by

“Chemical compounds found in cannabis may help to reduce brain damage following a stroke, new research has revealed.

Researchers at the University of Nottingham conducted a meta-analysis of experimental studies into cannabinoids; chemicals related to those found in cannabis, some of which also occur naturally in the body.

The findings showed that the compounds could reduce the size of stroke and improve .

Cannabinoids can be classified into those found naturally in the body (endocannabinoids), those made artificially (synthetic cannabinoids) or those derived from extracts from the plant cannabis sativa (phytocannabinoids).

The research, announced at the annual UK Stroke Forum, indicates that all three classes of cannabinoid could be effective in shrinking the area of the brain affected by stroke and in recovering neurological function.”

http://healthmedicinet.com/i/cannabis-compounds-may-limit-stroke-damage/

Compounds in cannabis could limit stroke damage

Posted on by

“Researchers at the University of Nottingham conducted a meta-analysis of experimental studies into cannabinoids; chemicals related to those found in cannabis, some of which also occur naturally in the body.

The findings showed that the compounds could reduce the size of stroke and improve neurological function.”

http://www.myscience.org.uk/news/2013/compounds_in_cannabis_could_limit_stroke_damage-2013-nottingham

The Inhibitory Effects of Cannabidiol on Systemic Malignant Tumors

Posted on by

“Cannabidiol may attenuate tumor growth in a number of other systemic malignancies.

Decreased tumor growth in pulmonary malignancies is seen after administration of cannabidiol.

Tumor metastasis also is markedly attenuated.

Similar attenuation of tumor growth is seen in breast malignancies.

The above examples clearly illustrate the significant antineoplastic effects of cannabidiol.

Hopefully, the next few years will see increased studies to fully and further evaluate these antineoplastic effects.”

https://www.ncbi.nlm.nih.gov/pubmed/23544909

http://www.jpsmjournal.com/article/S0885-3924(13)00115-2/fulltext#article-outline

http://www.thctotalhealthcare.com/category/cancer/

COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells.

Posted on by

Figure 7.

“Within the last decade, evidence has been accumulated to suggest an antitumorigenic action of cannabinoids elicited via induction of apoptosis and alternative anticarcinogenic mechanisms… cannabidiol has been shown to elicit pronounced proapoptotic or autophagic effects on different types of tumor cells

This study investigates the role of COX-2 and PPAR-γ in cannabidiol’s proapoptotic and tumor-regressive action. In lung cancer cell lines (A549, H460) and primary cells from a patient with lung cancer, cannabidiol elicited decreased viability associated with apoptosis… our data show a novel proapoptotic mechanism of cannabidiol involving initial upregulation of COX-2 and PPAR-γ…

Collectively, our data strengthen the notion that activation of PPAR-γ may present a promising target for lung cancer therapy.

In addition and to the best of our knowledge, this is the first report to provide an inhibitor-proven tumor-regressive mechanism of cannabidiolin vivo as well as a proapoptotic mechanism confirmed by use of primary lung tumor cells.

Against this background and considering recent findings supporting a profound antimetastatic action of cannabidiol, this cannabinoid may represent a promising anticancer drug.”

http://mct.aacrjournals.org/content/12/1/69.long

http://www.thctotalhealthcare.com/category/lung-cancer/

Study: Habitual Marijuana Smoking Not Associated With Increased Risk Of Lung Cancer

Posted on by

eNews Park Forest

“Subjects who regularly inhale cannabis smoke possess no greater risk of contracting lung cancer than do those who consume it occasionally or not at all, according to data published online ahead of print in the International Journal of Cancer.

An international team of investigators from Canada, New Zealand, the United Kingdom, and the United States analyzed data from six case-control studies involving over 5,000 subjects (2,159 cases and 2,985 controls) from around the world.

Authors concluded, “Results from our pooled analyses provide little evidence for an increased risk of lung cancer among habitual or long-term cannabis smokers.””

http://www.enewspf.com/latest-news/health-and-fitness/53910-study-habitual-marijuana-smoking-not-associated-with-increased-risk-of-lung-cancer.html

“Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium”  http://onlinelibrary.wiley.com/doi/10.1002/ijc.29036/abstract

http://www.thctotalhealthcare.com/category/lung-cancer/

Cannabinoids drug for inflammatory bowel

Posted on by

Medindia

“Researchers from the University of Bath, UK has found that Cannabinoids derived from Cannabis has found to be effective in the treatment of inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.

“The system that responds to cannabis in the brain is present and functioning in the lining of the gut,” lead researcher Dr. Karen Wright, of the University of Bath, explained to Reuters Health. “There is an increased presence of one component of this system during inflammatory bowel diseases,” she explained.

The report of the study was published in the Journal of Gastroenterology in which she has explained the location of CB1 and CB2 receptors in human colon tissue which binds to the Cannabinoid. She has used Human colon cell lines to establish the binding of the cannabinoid compounds and in her wound healing experiments.

Increased CB2 receptors are found in colonic tissue characteristic of inflammatory bowel disease. They found that the Cannabinoids helps in wound healing of the surface by CB1 related receptor mechanism.

“Cannabinoids, which we make ourselves, as well as synthetic Cannabinoids, can promote wound healing in the gut, which is extremely interesting given that inflammatory bowel disease involves damaged gut linings,” Wright said.”

http://www.medindia.net/news/view_news_main.asp?x=4578

Long-term cannabinoid type 2 receptor agonist therapy decreases Bacterial Translocation In Rats with cirrhosis and ascites.

Posted on by

“Intestinal hyper-permeability, impaired peritoneal macrophages (PMs) phagocytosis, and, bacterial translocation (BT) resulting in increased systemic and local infection/inflammation such as spontaneous bacterial peritonitis (SBP), together with increased tumor necrosis factor-α (TNFα) levels, are all implicated in the pathogenesis of cirrhosis-related complications.

Manipulation of cannabinoid receptors (CB1R and CB2R), which are expressed on the gut mucosa and PMs, has been reported to modulate intestinal inflammation and systemic inflammatory cytokines release. Our study aims to explore the effects of chronic CB1R/CB2R agonist/antagonist treatments on relevant abnormalities in cirrhotic ascitic rats…

CONCLUSIONS:

Our study suggests that CB2R agonist have the potential to treat BT and various relevant abnormalities through the inhibition of systemic/intestinal oxidative stress, inflammatory cytokines and TNFα releases in cirrhosis. Overall, chronic CB2R agonist treatment affects multiple approach mechanisms, and the direct effect on hyperdynamic circulation is only minor.”

http://www.ncbi.nlm.nih.gov/pubmed/24953022

Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference.

Posted on by

“The centrally expressed cannabinoid receptor (CB1) has been considered a potential therapeutic target in treating alcoholism.

Though CB1 receptors have been shown to modulate primary and conditioned ethanol reward, much of this research employed animal models that require ethanol ingestion or oral routes of administration. This is problematic considering CB1 antagonist drugs have high anorectic liability and have been used clinically in the treatment of obesity. Therefore, the present study examined CB1 antagonism in DBA/2J mice using an unbiased ethanol-induced conditioned place preference (CPP) procedure, a paradigm that does not require ethanol ingestion…

Results from the present study appear inconsistent with other studies that have demonstrated a role for CB1 antagonism in ethanol reward using oral administration paradigms.

Our findings suggest that CB1 antagonism may have greater involvement in consummatory behavior than ethanol reward.”

http://www.ncbi.nlm.nih.gov/pubmed/24954022

http://www.thctotalhealthcare.com/category/addiction/

A Vapourized Δ9-Tetrahydrocannabinol (Δ9-THC) Delivery System Part II: Comparison of Behavioural Effects of Pulmonary Versus Parenteral Cannabinoid Exposure in Rodents.

Posted on by

“These results suggest vapourized Δ9-THC administration produces behavioural effects qualitatively different from those induced by IP administration in rodents. Furthermore, vapourized Δ9-THC delivery in rodents may produce behavioural effects more comparable to those observed in humans. We conclude that some of the conflicting findings in animal and human cannabinoid studies may be related to pharmacokinetic differences associated with route of administration.”

http://www.ncbi.nlm.nih.gov/pubmed/24956154

Current and future drugs for treatment of MS-associated bladder dysfunction.

Posted on by

“A majority of patients diagnosed with multiple sclerosis (MS) will develop lower urinary tract symptoms (LUTS) during the course of the disease…

Cannabis extracts have shown some promise but has still not gained wide acceptance…

http://www.ncbi.nlm.nih.gov/pubmed/24954496

http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/